DÄ internationalArchiveReferences
References

cme

Actinic Keratosis and Cutaneous Squamous Cell Carcinoma

Dtsch Arztebl Int 2019; 116: 616-26. DOI: 10.3238/arztebl.2019.0616

Gutzmer, R; Wiegand, S; Kölbl, O; Wermker, K; Heppt, M; Berking, C

1.Deutsche Krebsgesellschaft DKg, AWMF: S3-Leitlinie Aktinische Keratose und Plattenepithelkarzinom der Haut. Langversion 1.0. www.awmf.org/uploads/tx_szleitlinien/032–022OLk_S3_Aktinische_Keratosen-Plattenepithelkarzinom-PEK_2019–07.pdf (last accessed on 3 August 2019).
2.Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A: The natural history of actinic keratosis: a systematic review. Br J Dermatol 2013; 169: 502–18 CrossRef MEDLINE
3.Hillen U, Ulrich M, Alter M, et al.: [Cutaneous squamous cell carcinoma: a review with consideration of special patient groups]. Hautarzt 2014; 65: 590–9 CrossRef MEDLINE
4.Jansen MHE, Kessels J, Nelemans PJ, et al.: Randomized trial of four treatment approaches for actinic keratosis. N Engl J Med 2019; 380: 935–46 CrossRef MEDLINE
5.Heppt MV, Steeb T, Leiter U, Berking C: Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. J Eur Acad Dermatol Venereol 2019; 33: 863–73 CrossRef MEDLINE
6.Heppt MV, Steeb T, Ruzicka T, Berking C: Cryosurgery combined with topical interventions for actinic keratosis: a systematic review and meta-analysis. Br J Dermatol 2019; 180: 740–8 CrossRef MEDLINE
7.Steeb T, Schlager JG, Kohl C, Ruzicka T, Heppt MV, Berking C: Laser-assisted photodynamic therapy for actinic keratosis: a systematic review and meta-analysis. J Am Acad Dermatol 2019; 80: 947–56 CrossRef MEDLINE
8.Stratigos A, Garbe C, Lebbe C, et al.: Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer 2015; 51: 1989–2007 CrossRef MEDLINE
9.Loser CR, Rompel R, Mohrle M, et al.: S1 guideline: microscopically controlled surgery. J Dtsch Dermatol Ges 2015; 13: 942–51 CrossRef MEDLINE
10.Allen JE, Stolle LB: Utility of sentinel node biopsy in patients with high-risk cutaneous squamous cell carcinoma. Eur J Surg Oncol 2015; 41: 197–200 CrossRef MEDLINE
11.Leiter U, Gutzmer R, Alter M, et al.: [Cutaneous squamous cell carcinoma]. Hautarzt 2016; 67: 857–66 CrossRef MEDLINE
12.Krediet JT, Beyer M, Lenz K, et al.: Sentinel lymph node biopsy and risk factors for predicting metastasis in cutaneous squamous cell carcinoma. Br J Dermatol 2015; 172: 1029–36 CrossRef MEDLINE
13.Newlands C, Currie R, Memon A, Whitaker S, Woolford T: Non-melanoma skin cancer: United Kingdom national multidisciplinary guidelines. J Laryngol Otol 2016; 130: 125–32 CrossRef MEDLINE PubMed Central
14.Mendenhall WM, Amdur RJ, Hinerman RW, et al.: Skin cancer of the head and neck with perineural invasion. Am J Clin Oncol 2007; 30: 93–6 CrossRef MEDLINE
15.Porceddu SV, Bressel M, Poulsen MG, et al.: Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: the randomized phase III TROG 05.01 trial. J Clin Oncol 2018; 36: 1275–83 CrossRef MEDLINE
16.Erkan S, Savundra JM, Wood B, Acharya AN, Rajan GP: Clinical perineural invasion of the trigeminal and facial nerves in cutaneous head and neck squamous cell carcinoma: outcomes and prognostic implications of multimodality and salvage treatment. Head Neck 2017; 39: 1280–6 CrossRef MEDLINE
17.Jambusaria-Pahlajani A, Miller CJ, Quon H, Smith N, Klein RQ, Schmults CD: Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes. Dermatol Surg 2009; 35: 574–85 CrossRef MEDLINE
18.Veness MJ: Treatment recommendations in patients diagnosed with high-risk cutaneous squamous cell carcinoma. Australas Radiol 2005; 49: 365–76 CrossRef MEDLINE
19.Han A, Ratner D: What is the role of adjuvant radiotherapy in the treatment of cutaneous squamous cell carcinoma with perineural invasion? Cancer 2007; 109: 1053–9 CrossRef MEDLINE
20.Tanvetyanon T, Padhya T, McCaffrey J, et al.: Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck 2015; 37: 840–5 CrossRef MEDLINE
21.Amoils M, Lee CS, Sunwoo J, et al.: Node-positive cutaneous squamous cell carcinoma of the head and neck: survival, high-risk features, and adjuvant chemoradiotherapy outcomes. Head Neck 2017; 39: 881–5 CrossRef MEDLINE
22.Wang JT, Palme CE, Morgan GJ, Gebski V, Wang AY, Veness MJ: Predictors of outcome in patients with metastatic cutaneous head and neck squamous cell carcinoma involving cervical lymph nodes: improved survival with the addition of adjuvant radiotherapy. Head Neck 2012; 34: 1524–8 CrossRef MEDLINE
23.Behshad R, Garcia-Zuazaga J, Bordeaux JS: Systemic treatment of locally advanced nonmetastatic cutaneous squamous cell carcinoma: a review of the literature. Br J Dermatol 2011; 165: 1169–77 CrossRef MEDLINE
24.Alter M, Satzger I, Mattern A, Kapp A, Gutzmer R: Treatment of advanced cutaneous squamous cell carcinomas with epidermal growth factor receptor inhibitors. Dermatology 2013; 227: 289–94 CrossRef MEDLINE
25.Maubec E, Petrow P, Scheer-Senyarich I, et al.: Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011; 29: 3419–26 CrossRef MEDLINE
26.Foote MC, McGrath M, Guminski A, et al.: Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol 2014; 25: 2047–52 CrossRef MEDLINE
27.Hitt R, Irigoyen A, Cortes-Funes H, et al.: Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol 2012; 23: 1016–22 CrossRef MEDLINE
28.Vermorken JB, Mesia R, Rivera F, et al.: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116–27 CrossRef MEDLINE
29.Schaper K, Kother B, Hesse K, Satzger I, Gutzmer R: The pattern and clinicopathological correlates of programmed death-ligand 1 expression in cutaneous squamous cell carcinoma. Br J Dermatol 2017; 176: 1354–6 CrossRef MEDLINE
30.Migden MR, Rischin D, Schmults CD, et al.: PD-1-Blockade with Cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 2018; 379: 341–51 CrossRef MEDLINE
31.Euvrard S, Kanitakis J, Claudy A: Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681–91 CrossRef MEDLINE
32.Ulrich C, Arnold R, Frei U, Hetzer R, Neuhaus P, Stockfleth E: Skin changes following organ transplantation: an interdisciplinary challenge. Dtsch Arztebl Int 2014; 111: 188–94 VOLLTEXT
33.Heppt MV, Steeb T, Niesert AC, et al.: Local interventions for actinic keratosis in organ transplant recipients: a systematic review. Br J Dermatol 2019; 180: 43–50 CrossRef MEDLINE
34.Cheng JY, Li FY, Ko CJ, Colegio OR: Cutaneous squamous cell carcinomas in solid organ transplant recipients compared with immunocompetent patients. JAMA Dermatol 2018; 154: 60–6 CrossRef MEDLINE PubMed Central
35.Tio M, Rai R, Ezeoke OM, et al.: Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. Eur J Cancer 2018; 104: 137–44 CrossRef MEDLINE
36.Gutzmer R, Koop A, Meier F, et al.: Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer 2017; 75: 24–32 CrossRef MEDLINE
37.Alter M, Satzger I, Schrem H, Kaltenborn A, Kapp A, Gutzmer R: Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients. J Dtsch Dermatol Ges 2014; 12: 480–8 CrossRef MEDLINE
38.Weinstock MA, Thwin SS, Siegel JA, et al.: Chemoprevention of basal and squamous cell carcinoma with a single course of fluorouracil, 5%, cream: a randomized clinical trial. JAMA Dermatol 2018; 154: 167–74 CrossRef MEDLINE PubMed Central
39.Chen AC, Martin AJ, Choy B, et al.: A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med 2015; 373: 1618–26 CrossRef MEDLINE
40.Brantsch KD, Meisner C, Schonfisch B, et al.: Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 2008; 9: 713–20 CrossRef MEDLINE
e1.Wermker K, Belok F, Schipmann S, Klein M, Schulze HJ, Hallermann C: Prediction model for lymph node metastasis and recommendations for elective neck dissection in lip cancer. J Craniomaxillofac Surg 2015; 43: 545–52 CrossRef MEDLINE
e2.Wermker K, Kluwig J, Schipmann S, Klein M, Schulze HJ, Hallermann C: Prediction score for lymph node metastasis from cutaneous squamous cell carcinoma of the external ear. Eur J Surg Oncol 2015; 41: 128–35 CrossRef MEDLINE
e3.Foley P, Merlin K, Cumming S, et al.: A comparison of cryotherapy and imiquimod for treatment of actinic keratoses: lesion clearance, safety, and skin quality outcomes. J Drugs Dermatol 2011; 10: 1432–8.
e4.Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E: A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007; 157(Suppl 2): 34–40 CrossRef MEDLINE
e5.Simon JC, Dominicus R, Karl L, Rodriguez R, Willers C, Dirschka T: A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis. J Eur Acad Dermatol Venereol 2015; 29: 881–9 CrossRef MEDLINE
e6.Zane C, Facchinetti E, Rossi MT, Specchia C, Ortel B, Calzavara-Pinton P: Cryotherapy is preferable to ablative CO2 laser for the treatment of isolated actinic keratoses of the face and scalp: a randomized clinical trial. Br J Dermatol 2014; 170: 1114–21 CrossRef MEDLINE
e7.Kaufmann R, Spelman L, Weightman W, et al.: Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol 2008; 158: 994–9 CrossRef MEDLINE
e8.Morton C, Campbell S, Gupta G, et al.: Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol 2006; 155: 1029–36 CrossRef MEDLINE
e9.Ostertag JU, Quaedvlieg PJ, van der Geer S, et al.: A clinical comparison and long-term follow-up of topical 5-fluorouracil versus laser resurfacing in the treatment of widespread actinic keratoses. Lasers Surg Med 2006; 38: 731–9 CrossRef MEDLINE
e10.McEwan LE, Smith JG: Topical diclofenac/hyaluronic acid gel in the treatment of solar keratoses. Australas J Dermatol 1997; 38: 187–9 CrossRef MEDLINE
e11.Pflugfelder A, Welter AK, Leiter U, et al.: Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. J Eur Acad Dermatol Venereol 2012; 26: 48–53 CrossRef MEDLINE
e12.Stockfleth E, Kerl H, Zwingers T, Willers C: Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol 2011; 165: 1101–8 CrossRef MEDLINE
e13.Ulrich C, Johannsen A, Rowert-Huber J, Ulrich M, Sterry W, Stockfleth E: Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. Eur J Dermatol 2010; 20: 482–8 CrossRef MEDLINE
e14.Wolf JE, Jr., Taylor JR, Tschen E, Kang S: Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40: 709–13 CrossRef MEDLINE
e15.Zane C, Facchinetti E, Rossi MT, Specchia C, Calzavara-Pinton PG: A randomized clinical trial of photodynamic therapy with methyl aminolaevulinate vs. diclofenac 3% plus hyaluronic acid gel for the treatment of multiple actinic keratoses of the face and scalp. Br J Dermatol 2014; 170: 1143–50 CrossRef MEDLINE
e16.Gebauer K, Brown P, Varigos G: Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol 2003; 44: 40–3 CrossRef
e17.Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y: Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002; 146: 94–100 CrossRef MEDLINE
e18.Stockfleth E, Zwingers T, Willers C: Recurrence rates and patient assessed outcomes of 0.5% 5-fluorouracil in combination with salicylic acid treating actinic keratoses. Eur J Dermatol 2012; 22: 370–4 CrossRef MEDLINE
e19.Pomerantz H, Hogan D, Eilers D, et al.: Long-term efficacy of topical fluorouracil cream, 5%, for treating actinic keratosis: a randomized clinical trial. JAMA Dermatol 2015; 151: 952–60 CrossRef MEDLINE
e20.Tanghetti E, Werschler P: Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. J Drugs Dermatol 2007; 6: 144–7.
e21.Loven K, Stein L, Furst K, Levy S: Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 2002; 24: 990–1000 CrossRef
e22.Garbe C, Basset-Seguin N, Poulin Y, et al.: Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0.015% gel: a randomized, controlled 12-month study. Br J Dermatol 2016; 174: 505–13 CrossRef MEDLINE
e23.Moggio E, Arisi M, Zane C, Calzavara-Pinton I, Calzavara-Pinton P: A randomized split-face clinical trial analyzing daylight photodynamic therapy with methyl aminolaevulinate vs ingenol mebutate gel for the treatment of multiple actinic keratoses of the face and the scalp. Photodiagnosis Photodyn Ther 2016; 16: 161–5 CrossRef MEDLINE
e24.Zane C, Fabiano A, Arisi M, Calzavara-Pinton P: A randomized split-face clinical trial of photodynamic therapy with methyl aminolevulinate versus ingenol mebutate gel for the treatment of multiple actinic keratoses of the face and scalp. Dermatology 2016; 232: 472–7 CrossRef MEDLINE
e25.Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B: Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012; 366: 1010–9 CrossRef MEDLINE
e26.Lebwohl M, Shumack S, Stein Gold L, Melgaard A, Larsson T, Tyring SK: Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol 2013; 149: 666–70 CrossRef MEDLINE
e27.Sinnya S, Tan JM, Prow TW, et al.: A randomized, phase IIa exploratory trial to assess the safety and preliminary efficacy of LEO 43204 in patients with actinic keratosis. Br J Dermatol 2016; 174: 305–11 CrossRef MEDLINE
e28.Anderson L, Schmieder GJ, Werschler WP, et al.: Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol 2009; 60: 934–43 CrossRef MEDLINE
e29.Hanke CW, Beer KR, Stockfleth E, Wu J, Rosen T, Levy S: Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol 2010; 62: 573–81 CrossRef MEDLINE
e30.Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S: Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol 2010; 62: 582–90 CrossRef MEDLINE
e31.Alomar A, Bichel J, McRae S: Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 2007; 157: 133–41 CrossRef MEDLINE
e32.Chen K, Yap LM, Marks R, Shumack S: Short-course therapy with imiquimod 5% cream for solar keratoses: a randomized controlled trial. Australas J Dermatol 2003; 44: 250–5 CrossRef
e33.Jorizzo J, Dinehart S, Matheson R, et al.: Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 2007; 57: 265–8 CrossRef MEDLINE
e34.Korman N, Moy R, Ling M, et al.: Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005; 141: 467–73 CrossRef MEDLINE
e35.Kose O, Koc E, Erbil AH, Caliskan E, Kurumlu Z: Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis. J Dermatolog Treat 2008; 19: 159–63 CrossRef MEDLINE
e36.Lebwohl M, Dinehart S, Whiting D, et al.: Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50: 714–21 CrossRef MEDLINE
e37.Ooi T, Barnetson RS, Zhuang L, et al.: Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. Br J Dermatol 2006; 154: 72–8 CrossRef MEDLINE
e38.Stockfleth E, Meyer T, Benninghoff B, et al.: A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 2002; 138: 1498–502 CrossRef MEDLINE
e39.Szeimies RM, Gerritsen MJ, Gupta G, et al.: Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004; 51: 547–55 CrossRef MEDLINE
e40.Ulrich C, Bichel J, Euvrard S, et al.: Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007; 157(Suppl 2): 25–31 CrossRef MEDLINE PubMed Central
e41.Smith S, Piacquadio D, Morhenn V, Atkin D, Fitzpatrick R: Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol 2003; 2: 629–35.
e42.Szeimies RM, Radny P, Sebastian M, et al.: Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. Br J Dermatol 2010; 163: 386–94 CrossRef MEDLINE
e43.Dirschka T, Radny P, Dominicus R, et al.: Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. Br J Dermatol 2012; 166: 137–46 CrossRef MEDLINE
e44.Holzer G, Pinkowicz A, Radakovic S, Schmidt JB, Tanew A: Randomized controlled trial comparing 35% trichloroacetic acid peel and 5-aminolaevulinic acid photodynamic therapy for treating multiple actinic keratosis. Br J Dermatol 2017; 176: 1155–61 CrossRef
e45.Jeffes EW, McCullough JL, Weinstein GD, Kaplan R, Glazer SD, Taylor JR: Photodynamic therapy of actinic keratoses with topical aminolaevulinic acid hydrochloride and fluorescent blue light. J Am Acad Dermatol 2001; 45: 96–104 CrossRef MEDLINE
e46.Moloney FJ, Collins P: Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolevulinic acid photodynamic therapy for extensive scalp actinic keratosis. Br J Dermatol 2007; 157: 87–91 CrossRef MEDLINE
e47.Piacquadio DJ, Chen DM, Farber HF, et al.: Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol 2004; 140: 41–6 CrossRef MEDLINE
e48.Reinhold U, Dirschka T, Ostendorf R, et al.: A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz(®) ) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED(®) lamp. Br J Dermatol 2016; 175: 696–705 CrossRef MEDLINE
e49.Pariser DM, Lowe NJ, Stewart DM, et al.: Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 2003; 48: 227–32 CrossRef MEDLINE
e50.Pariser D, Loss R, Jarratt M, et al.: Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2008; 59: 569–76 CrossRef MEDLINE
e51.Szeimies RM, Matheson RT, Davis SA, et al.: Topical methyl aminolevulinate photodynamic therapy using red light-emitting diode light for multiple actinic keratoses: a randomized study. Dermatol Surg 2009; 35: 586–92 CrossRef MEDLINE
e52.Dragieva G, Prinz BM, Hafner J, et al.: A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol 2004; 151: 196–200 CrossRef MEDLINE
e53.Neittaanmaki-Perttu N, Gronroos M, Karppinen T, Snellman E, Rissanen P: Photodynamic therapy for actinic keratoses: a randomized prospective non-sponsored cost-effectiveness study of daylight-mediated treatment compared with light-emitting diode treatment. Acta Derm Venereol 2016; 96: 241–4 CrossRef MEDLINE
e54.Wiegell SR, Haedersdal M, Eriksen P, Wulf HC: Photodynamic therapy of actinic keratoses with 8% and 16% methyl aminolaevulinate and home-based daylight exposure: a double-blinded randomized clinical trial. Br J Dermatol 2009; 160: 1308–14 CrossRef MEDLINE
e55.Wiegell SR, Fabricius S, Stender IM, et al.: A randomized, multicentre study of directed daylight exposure times of 1(1/2) vs. 2(1/2) h in daylight-mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp. Br J Dermatol 2011; 164: 1083–90 CrossRef MEDLINE
e56.Chren MM, Linos E, Torres JS, Stuart SE, Parvataneni R, Boscardin WJ: Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol 2013; 133: 1188–96 CrossRef MEDLINEPubMed Central
e57.Lansbury L, Bath-Hextall F, Perkins W, Stanton W, Leonardi-Bee J: Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ 2013; 347: f6153 CrossRef MEDLINE PubMed Central
e58.Brodland DG, Zitelli JA: Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol 1992; 27: 241–8 CrossRef
e59.Bertino G, Sersa G, De Terlizzi F, et al.: European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: results of the treatment of skin cancer. Eur J Cancer 2016; 63: 41–52 CrossRef MEDLINE
e60.Guminski A, Lim AM, Khushalani NI, et al.: Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up. J Clin Oncol 2019; 37: 9526 CrossRef
e61.Migden MR, Khushalani NI, Chang AL, et al.: Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti–PD-1, in patients with locally advanced cutaneous squamous cell carcinoma. J Clin Oncol 2019; 37: 6015 CrossRef
e62.Maubec E, Boubaya M, Petrow P, et al.: Pembrolizumab as first-line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC): Phase 2 results from CARSKIN. J Clin Oncol 2019; 37: 9547 CrossRef
e63.Hillen U, Leiter U, Haase S, et al.: Advanced cutaneous squamous cell carcinoma: a retrospective analysis of patient profiles and treatment patterns-results of a non-interventional study of the DeCOG. Eur J Cancer 2018; 96: 34–43 CrossRef MEDLINE